RightFit
RecruitingPhase not listed

Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer

TEMPUS ONCO-OLIVIA Registry

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
No age limits stated
Sex
All sexes
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study uses Olivia, an AI-powered health app, to collect medical records and patients’ reports about their health for cancer research. It is for adults and children with cancer. An added study is for children with acute myeloid leukemia (AML), a blood cancer.

This study entails enrolling participants that have been diagnosed with cancer to Olivia, a commercially available AI-enabled personal health platform developed by Tempus. Olivia will serve as the primary interface for eConsent and enrollment into the registry. The platform will also help create a retrospective and prospective registry by working with over 1,000 healthcare systems to combine electronic health records (EHR) and Patient Reported Outcomes (PROs) in a single spot. There may be sub-studies as an add-on to this parent protocol. The sub-studies will address specific goals of the targeted research activities and will usually include additional information specific to each research study.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Main study: People of any age with cancer confirmed by lab testing and listed in their medical record. Some groups may have more requirements.
  • Main study: Must receive care in the United States or its territories.
  • Both studies: You or someone legally allowed to act for you must agree online to join through Olivia. Children must agree again at age 18, if needed.
  • Both studies: Must allow the study to get your medical records.
  • Both studies: Must have access to a smartphone, tablet, or internet-connected device, on your own or through a caregiver.
  • AML study: Children must have confirmed AML of a type listed in the study rules.
  • AML study: Must receive or have received care in the United States or its territories.
  • AML study: For a child who has died, someone legally allowed to act for them must agree online to their participation.

Who can't join

  • AML study: Cannot join if AML is suspected but has not been confirmed.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

ONCO-OLIVIA Registry: Inclusion Criteria: * Adults or children (all ages) with a pathologically confirmed diagnosis of cancer (solid tumor or hematologic malignancy) documented in the medical record; disease-specific cohorts may further define subtypes (e.g., stage, biomarker) * Receiving care in the United States and/or U.S. Territories * Participant (and/or legally authorized representative) is able and willing to provide electronic informed consent/permission and authorization via Olivia; with re-consent at age of eighteen if applicable * Willing to authorize medical record retrieval under HIPAA Right of Access and/or TEFCA IAS * Access to a smartphone, tablet, or web-enabled device for remote participation (directly or via caregiver) for eConsent and optional surveys Exclusion Criteria: * Not Applicable Substudy OLV002: Pediatric Acute Myeloid Leukemia (pAML): Inclusion Criteria: * Receiving or have received care in the United States and/or U.S. Territories * Participant (and/or legally authorized representative) is able and willing to provide electronic informed consent/permission and authorization via the platform; with re-consent at age of eighteen if applicable * Legally authorized representative of participant who is deceased is able and willing to provide electronic informed consent/permission and authorization via the platform * Willing to authorize medical record retrieval under HIPAA Right of Access and/or TEFCA IAS * Access to a smartphone, tablet, or web-enabled device for remote participation (directly or via caregiver) for eConsent and cohort dependent PROs/surveys * Pediatric patients with a confirmed diagnosis of Acute Myeloid Leukemia (AML) including the following AML subtypes per WHO/ICC classification: AML with core-binding factor rearrangements (AML-CBF), AML with inv(16) (AML-NV16), acute promyelocytic leukemia (APL), AML with KMT2A rearrangement (AML-KMT2A), AML with mutated NPM1 (AML-NPM1), AML with bZIP CEBPA mutations (AML-bZIP), AML with MECOM rearrangement Exclusion Criteria: \- Suspected but unconfirmed acute myeloid leukemia

Study sites (1)

IL